Introduction
Material and methods
Data sources
SQRTPA
SOReg
Study cohort
Ethical considerations
Data
Statistical analysis
Results
Baseline patient and procedure characteristics in the overall cohort
N = 6115 (100 %) | |
---|---|
Age median (IQR) | 46 (33–59) |
Sex | |
Male | 1234 (20.2) |
Female | 4881 (79.8) |
Indication for thyroidectomy | |
Recurrent cyst | 12 (0.2) |
Completion operation | 17 (0.3) |
Excluding malignancy | 457 (7.5) |
Malignancy | 956 (15.6) |
Compression | 1586 (25.9) |
Thyrotoxicosis | 3063 (50.1) |
Other | 24 (0.4) |
Lymphnode dissection | |
Yes | 1068 (17.5) |
No | 5047 (82.5) |
Gland weight (grams) | 74.2 (±94.0) |
Oral perioperative calcium treatment | |
Yes | 2055 (33.6) |
No | 4060 (66.4) |
Intravenous calcium treatment | |
Yes | 250 (4.1) |
No | 5865 (95.9) |
Peroral calcium treatment | |
At discharge (yes/no) | 1776 (29.0)/4339 (71.0) |
At 6 weeks follow-up (yes/no) | 841 (13.8)/4793 (78.4) |
At 6 months follow-up (yes/no) | 290 (4.7)/5184 (84.8) |
Total serum calcium | |
Postoperative day 1 | 2.13 (±0.20) |
At 6 weeks follow-up | 2.30 (±0.17) |
At 6 months follow-up | 2.25 (±0.17) |
Peroral vitamin D treatment | |
At discharge (yes/no) | 909 (14.9)/5206 (85.1) |
At 6 weeks follow-up (yes/no) | 554 (9.1)/5087 (83.2) |
At 6 months follow-up (yes/no) | 214 (3.5)/5333 (87.2) |
Patient and procedure characteristics in patients with and without previous GBP
No previous GBP N = 6090 (100 %) | Previous GBP N = 25 (100 %) |
p value | |
---|---|---|---|
Age median (IQR) | 46 (33–59) | 48 (41–52) | 0.977 |
Sex | |||
Male | 1230 (20.2) | 4 (16.0) | 0.602 |
Female | 4860 (79.8) | 21 (84.0) | |
Indication for thyroidectomy | |||
Recurrent cyst | 12 (0.2) | 0 (0.0) | 0.015 |
Completion operation | 17 (0.3) | 0 (0.0) | |
Excluding malignancy | 454 (7.5) | 3 (12.0) | |
Malignancy | 949 (15.6) | 7 (28.0) | |
Compression | 1575 (25.9) | 11 (44.0) | |
Thyreotoxicosis | 3059 (50.2) | 4 (16.0) | |
Other | 24 (0.4) | 0 (0.0) | |
Lymphnode dissection | |||
Yes | 1061 (17.4) | 7 (28.0) | 0.164 |
No | 5029 (82.6) | 18 (72.0) | |
Gland weight (grams) | 74.1 (±94.0) | 80.7 (±72.2) | 0.748 |
Oral perioperative calcium treatment | |||
Yes | 2047 (33.6) | 8 (32.0) | 0.865 |
No | 4043 (66.4) | 17 (68.0) | |
Intravenous calcium treatment | |||
Yes | 248 (4.1) | 2 (8.0) | 0.322 |
No | 5842 (95.9) | 23 (92.0) | |
Peroral calcium treatment | |||
At discharge (yes/no) | 1770 (29.1)/4320 (70.9) | 6 (24.0)/19 (76.0) | 0.578 |
At 6 weeks follow-up (yes/no) | 837 (13.7)/4773 (78.4) | 4 (16.0)/20 (80.0) | 0.651 |
At 6 months follow-up (yes/no) | 288 (4.7)/5163 (84.8) | 2 (8.0)/21 (84.0) | 0.373 |
Total serum calcium | |||
Postoperative day 1 | 2.12 (±0.20) | 2.13 (±0.16) | 0.997 |
At 6 weeks follow-up | 2.30 (±0.17) | 2.27 (±0.13) | 0.305 |
At 6 months follow-up | 2.25 (±0.17) | 2.26 (±0.10) | 0.901 |
Peroral vitamin D treatment | |||
At discharge (yes/no) | 904 (14.8)/5186 (85.2) | 5 (20.0)/20 (80.0) | 0.470 |
At 6 weeks follow-up (yes/no) | 551 (9.0)/5066 (83.2) | 3 (12.0)/21 (84.0) | 0.616 |
At 6 months follow-up (yes/no) | 212 (3.5)/5311 (87.2) | 2 (8.0)/22 (88.0) | 0.278 |
Logistic regression analysis of hypocalcemia, vitamin D and calcium treatment at discharge and follow-up in the whole cohort
Factor | In hospital i.v. calcium | Per oral calcium at discharge | Per oral calcium at 6 weeks | Per oral calcium at 6 months | ||||
---|---|---|---|---|---|---|---|---|
OR (95 % CI) | ORa (95 % CI) | OR (95 % CI) | ORa (95 % CI) | OR (95 % CI) | ORa (95 % CI) | OR (95 % CI) | ORa (95 % CI) | |
Age | 0.98 (0.97–0.98) | 0.98 (0.97–0.99) | 1.00 (1.01–1.42) | 0.99 (0.99–0.99) | 1.00 (0.99–1.00) | 1.00 (0.99–1.00) | 1.00 (0.99–1.00) | 0.99 (0.99–1.00) |
Lymph node dissection | 1.67 (1.24–2.23) | 2.04 (1.48–2.82) | 2.20 (1.92–2.52) | 2.49 (2.16–2.89) | 2.03 (1.72–2.40) | 2.26 (1.88–2.70) | 2.85 (2.22–3.66) | 2.97 (2.27–3.88) |
Indication for surgery | 1.09 (1.03–1.16) | 1.06 (0.99–1.14) | 1.05 (1.02–1.07) | 1.07 (1.04–1.10) | 1.03 (1.00–1.07) | 1.07 (1.02–1.11) | 0.97 (0.92–1.02) | 1.01 (0.94–1.08) |
Gender | 0.84 (0.60–1.17) | 0.85 (0.60–1.19) | 1.02 (0.89–1.17) | 0.94 (0.81–1.08) | 1.06 (0.89–1.27) | 0.97 (0.81–1.16) | 1.10 (0.83–1.47) | 0.94 (0.70–1.26) |
Previous GBP | 2.05 (0.48–8.74) | 2.07 (0.48–9.07) | 0.77 (0.31–1.93) | 0.75 (0.29–1.91) | 1.14 (0.39–3.35) | 1.11 (0.37–3.31) | 1.71 (0.40–7.32) | 1.45 (0.33–6.36) |
Factor | Per oral vitamin D at discharge | Per oral vitamin D at 6 weeks | Per oral vitamin D at 6 months | |||
---|---|---|---|---|---|---|
OR (95 % CI) | ORa (95 % CI) | OR (95 % CI) | ORa (95 % CI) | OR (95 % CI) | ORa (95 % CI) | |
Age | 0.99 (0.98–0.99) | 0.99 (0.98–0.99) | 0.99 (0.99–1.00) | 0.99 (0.99–1.00) | 1.00 (0.99–1.00) | 0.99 (0.99–1.00) |
Lymph node dissection | 2.17 (1.84–2.55) | 2.52 (2.12–3.01) | 2.00 (1.64–2.44) | 2.29 (1.85–2.84) | 2.72 (2.04–3.62) | 2.85 (2.09–3.88) |
Indication for surgery | 1.04 (1.01–1.08) | 1.05 (1.01–1.10) | 1.04 (1.00–1.08) | 1.05 (1.00–1.11) | 0.98 (0.92–1.04) | 1.02 (0.94–1.10) |
Gender | 0.91 (0.76–1.09) | 0.84 (0.70–1.01) | 0.92 (0.73–1.15) | 0.85 (0.67–1.07) | 1.12 (0.80–1.55) | 0.95 (0.68–1.34) |
Previous GBP | 1.43 (0.54–3.83) | 1.37 (0.50–3.76) | 1.31 (0.39–4.42) | 1.25 (0.36–4.27) | 2.28 (0.53–9.74) | 2.01 (0.46–8.77) |
Endpoints in patients with and without previous GBP in the nested case-control group
No previous GBP N = 25 (100 %) | Previous GBP N = 25 (100 %) |
p value | |
---|---|---|---|
Age median (IQR) | 48 (41–52) | 48 (41–52) | 1.000 |
Sex | |||
Male | 4 (16.0) | 4 (16.0) | 1.000 |
Female | 21 (84.0) | 21 (84.0) | |
Indication for thyroidectomy | |||
Recurrent cyst | 0 (0.0) | 0 (0.0) | 1.000 |
Completion operation | 0 (0.0) | 0 (0.0) | |
Excluding malignancy | 3 (12.0) | 3 (12.0) | |
Malignancy | 7 (28.0) | 7 (28.0) | |
Compression | 11 (44.0) | 11 (44.0) | |
Thyreotoxicosis | 4 (16.0) | 4 (16.0) | |
Other | 0 (0.0) | 0 (0.0) | |
Lymphnode dissection | |||
Yes | 7 (28.0) | 7 (28.0) | 1.000 |
No | 18 (72.0) | 18 (72.0) | |
Gland weight (grams) | 74.0 (±61.7) | 80.7 (±72.2) | 0.737 |
Oral perioperative calcium treatment | |||
Yes | 10 (40.0) | 8 (32.0) | 0.556 |
No | 15 (60.0) | 17 (68.0) | |
Intravenous calcium treatment | |||
Yes | 0 (0.0) | 2 (8.0) | 0.149 |
No | 25 (100.0) | 23 (92.0) | |
Peroral calcium treatment | |||
At discharge (yes/no) | 8 (32.0)/17 (68.0) | 6 (24.0)/19 (76.0) | 0.935 |
At 6 weeks follow-up (yes/no) | 6 (24.0)/17 (68.0) | 4 (16.0)/20 (80.0) | 0.727 |
At 6 months follow-up (yes/no) | 2 (8.0)/20 (80.0) | 2 (8.0)/21 (84.0) | 0.599 |
Total serum calcium | |||
Postoperative day 1 | 2.16 (±0.15) | 2.13 (±0.16) | 0.450 |
At 6 weeks follow-up | 2.31 (±0.14) | 2.27 (±0.13) | 0.276 |
At 6 months follow-up | 2.14 (±0.18) | 2.26 (±0.10) | 0.160 |
Peroral vitamin D treatment | |||
At discharge (yes/no) | 6 (24.0)/19 (76.0) | 5 (20.0)/20 (80.0) | 0.733 |
At 6 weeks follow-up (yes/no) | 4 (16.0)/19 (76.0) | 3 (12.0)/21 (84.0) | 0.329 |
At 6 months follow-up (yes/no) | 1 (4.0)/21 (84.0) | 2 (8.0)/22 (88.0) | 0.188 |